HKPD

HONG KONG, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the "Company"), a leading provider of over-the-counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in Hong Kong, announced that it expects to implement a 1-for-20 reverse stock split, or consolidation of its issued and unissued Class A ordinary shares and Class B ordinary shares, par value $0.001 per share (the “Ordinary Shares”), effective at the opening of market of October 26, 2026 (the “Reverse Stock Split”). Trading in the Class A Ordinary Shares on a split-adjusted basis will continue on Nasdaq on October 26, 2026 under the symbol “HKPD.

HONG KONG, July 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the "Company"), a leading provider of over the counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that it received a notification letter (the “Notification Letter”) on July 14, 2026 from Nasdaq's Listing Qualifications Department indicating that the Company has been granted an additional 180 calendar day period, or until January 11, 2027, to regain compliance with the Nasdaq's minimum $1.00 closing bid price requirement (“the Minimum Bid Price Requirement”) as set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq.  To regain compliance with the Minimum Bid Price Requirement, the Company must maintain a closing bid price of the Company's Class A ordinary shares at least $1.00 per share for a minimum of ten consecutive business days on or prior to the end of the 180-day extension period, or January 11, 2027.